Contraception
Volume 82, Issue 4 , Pages 358-365 , October 2010

Endometrial safety of a novel monophasic combined oral contraceptive containing 0.02 mg ethinylestradiol and 2 mg chlormadinone acetate administered in a 24/4-day regimen over six cycles

  • Thomas Rabe

      Affiliations

    • University Women's Hospital, Voß-Str. 9, D-69115 Heidelberg, Germany
    • Corresponding Author InformationCorresponding author. Tel.: +49 6221 567913; fax: +49 6221 560713.
    • ,
  • Elena Hartschuh

      Affiliations

    • Neuenheimer Landstr. 60, D-69120 Heidelberg, Germany
    • ,
  • Torsten Wahlstrom

      Affiliations

    • Laboratory of Pathology, Eira Hospital, Tehtaan Katu 28, SF-00150 Helsinki, Finland
    • ,
  • Kornelia Höschen

      Affiliations

    • Grunenthal GmbH, D-52099 Aachen, Germany
    • ,
  • Simone König

      Affiliations

    • Grunenthal GmbH, D-52099 Aachen, Germany

Received 18 September 2009 ,Revised 13 April 2010 ,Accepted 14 April 2010.

References 

  1. Combined oral contraceptives . A statement by the Committee on Safety of Drugs. Br Med J. 1970;2:231–232
  2. Bettendorf G, Breckwoldtt M, Keller PJ, Kuhl H, Runnebaum B, Braendle W. Recommendations on oral contraception. Der Frauenarzt. 1997;38:1058–1062
  3. Jeffcoate TN. R.C.O.G. statement on oral contraceptives. Br Med J. 1970;2:293
  4. Druckmann R. Profile of the progesterone derivative chlormadinone acetate — pharmacodynamic properties and therapeutic applications. Contraception. 2009;79:272–281
  5. Plewig G, Cunliffe WJ, Binder N, Hoschen K. Efficacy of an oral contraceptive containing EE 0.03 mg and CMA 2 mg (Belara) in moderate acne resolution: a randomized, double-blind, placebo-controlled Phase III trial. Contraception. 2009;80:25–33
  6. Schramm G, Steffens D. Contraceptive efficacy and tolerability of chlormadinone acetate 2 mg/ethinylestradiol 0.03 mg (Belara). Results of a post-marketing surveillance study. Clin Drug Invest. 2002;22:221–231
  7. Schramm G, Steffens D. A 12-month evaluation of the CMA-containing oral contraceptive Belara: efficacy, tolerability and anti-androgenic properties. Contraception. 2003;67:305–312
  8. Winkler U, Daume E, Sudik R, et al. A comparative study of the hemostatic effects of two monophasic oral contraceptives containing 30 mu(g) ethinylestradiol and either 2 mg chlormadinone acetate or 150 mu(g) desogestrel. Eur J Contracept Reprod Health Care. 1999;4:145–154
  9. Worret I, Arp W, Zahradnik H, Andreas J, Binder N. Acne resolution rates: results of a single-blind, randomized, controlled, parallel Phase III trial with EE/CMA (Belara) and EE/LNG (Microgynon). Dermatology. 2001;203:38–44
  10. Zahradnik H, Goldberg J, Andreas J. Efficacy and safety of the new antiandrogenic oral contraceptive Belara. Contraception. 1998;57:103–109
  11. Zahradnik HP, Hanjalic-Beck A. Efficacy, safety and sustainability of treatment continuation and results of an oral contraceptive containing 30 mcg ethinyl estradiol and 2 mg chlormadinone acetate, in long-term usage (up to 45 cycles)—an open-label, prospective, noncontrolled, office-based Phase III study. Contraception. 2008;77:337–343
  12. Rabe T, Johanisson E. The influence of ethinyl estradiol 0.03 mg and chlormadinone acetate 2 mg on the thickness and histology of the endometrium. JATR. 2008;6:3–10
  13. Schramm G, Heckes B. Switching hormonal contraceptives to a chlormadinone acetate-containing oral contraceptive. The Contraceptive Switch Study. Contraception. 2007;76:84–90
  14. Coney P, DelConte A. The effects on ovarian activity of a monophasic oral contraceptive with 100 microg levonorgestrel and 20 microg ethinyl estradiol. Am J Obstet Gynecol. 1999;181:53–58
  15. Spona J, Feichtinger W, Kindermann C, Wunsch C, Brill K. Inhibition of ovulation by an oral contraceptive containing 100 micrograms levonorgestrel in combination with 20 micrograms ethinylestradiol. Contraception. 1996;54:299–304
  16. Ludicke F, Sullivan H, Spona J, Elstein M. Dose finding in a low-dose 21-day combined oral contraceptive containing gestodene. Contraception. 2001;64:243–248
  17. Endrikat J, Cronin M, Gerlinger C, Ruebig A, Schmidt W, Dusterberg B. Open, multicenter comparison of efficacy, cycle control, and tolerability of a 23-day oral contraceptive regimen with 20 microg ethinyl estradiol and 75 microg gestodene and a 21-day regimen with 20 microg ethinyl estradiol and 150 microg desogestrel. Contraception. 2001;64:201–207
  18. Spona J, Elstein M, Feichtinger W, et al. Shorter pill-free interval in combined oral contraceptives decreases follicular development. Contraception. 1996;54:71–77
  19. Rosenberg MJ, Waugh MS, Meehan TE. Use and misuse of oral contraceptives: risk indicators for poor pill taking and discontinuation. Contraception. 1995;51:283–288
  20. Sulak PJ, Kuehl TJ, Ortiz M, Shull BL. Acceptance of altering the standard 21-day/7-day oral contraceptive regimen to delay menses and reduce hormone withdrawal symptoms. Am J Obstet Gynecol. 2002;186:1142–1149
  21. Deligdisch L. Effects of hormone therapy on the endometrium. Mod Pathol. 1993;6:94–106
  22. Coenen C, Hollanders J, Rolland R, Spielmann D, Bulten J. The effects of a low-dose gestodene-containing oral contraceptive on endometrial histology in healthy women. Eur J Contracept Reprod Health Care. 1996;1:325–329
  23. Rabe T, Leppien G, Fossman W, Hessing C, Vladescu E, Runnebaum B. A study of the influence of a gestodene-containing triphasic oral contraceptive on endometrial morphology. Eur J Contracept Reprod Health Care. 1997;2:193–201
  24. World Health Organization . In: Technical Report Series 817: oral contraceptives and neoplasia. Report of the WHO scientific group. Geneva: WHO; 1992;p. 1–46
  25. European Medicines Association. Committee for Medicinal Products for Human Use: Guideline on clinical investigation of steroid contraceptives in women. EMEA/CPMP/EWP/519/98 Rev 1. London 2006:1–6.
  26. Brucker C, Hedon B, The HS, Höschen K, Binder N, Christoph A. Long-term efficacy and safety of a monophasic combined oral contraceptive containing 0.02 mg ethinylestradiol and 2 mg chlormadinone acetate administered in a 24/4-day regimen. Contraception. 2010;81:501–509
  27. Spona J, Binder N, Höschen K, Feichtinger W. Suppression of ovarian function by a combined oral contraceptive containing 0.02 mg ethinylestradiol and 2 mg chlormadinone acetate given in a 24/4-day regimen over 3 cycles. Fertil Steril. 2009 Aug 24;Epub ahead of print
  28. Albers JR, Hull SK, Wesley RM. Abnormal uterine bleeding. Am Fam Physician. 2004;69:1915–1926
  29. Brinton LA, Hoover RN. Estrogen replacement therapy and endometrial cancer risk: unresolved issues. The Endometrial Cancer Collaborative Group. Obstet Gynecol. 1993;81:265–271
  30. Kelley HW, Miles PA, Buster JE, Scragg WH. Adenocarcinoma of the endometrium in women taking sequential oral contraceptives. Obstet Gynecol. 1976;47:200–202
  31. Montgomery BE, Daum GS, Dunton CJ. Endometrial hyperplasia: a review. Obstet Gynecol Surv. 2004;59:368–378
  32. Silverberg SG, Makowski EL. Endometrial carcinoma in young women taking oral contraceptive agents. Obstet Gynecol. 1975;46:503–506
  33. Gambrell RD. The role of hormones in the etiology and prevention of endometrial cancer. Clin Obstet Gynaecol. 1986;13:695–723
  34. Pike MC, Peters RK, Cozen W, et al. Estrogen–progestin replacement therapy and endometrial cancer. J Natl Cancer Inst. 1997;89:1110–1116
  35. Deligdisch L. Hormonal pathology of the endometrium. Mod Pathol. 2000;13:285–294
  36. Hickey M, Salamonsen LA. Endometrial structural and inflammatory changes with exogenous progestogens. Trends Endocrinol Metab. 2008;19:167–174
  37. Rabe T, Leppien G, Kiesel L, et al. Light and electron microscopy changes in the endometrium caused by the administration of a norgestimate-containing oral contraceptive (Cilest). Geburtshilfe Frauenheilkd. 1986;46:883–891
  38. Rabe T, Nitsche D, Runnebaum B. The effects of monophasic and triphasic oral contraceptives on ovarian function and endometrial thickness. Eur J Contracept Reprod Health Care. 1997;2:39–51
  39. Thurman AR, Soper DE. Endometrial histology of depomedroxyprogesterone acetate users: a pilot study. Infect Dis Obstet Gynecol. 2006;2006:69402
  40. Chwalisz K, Garg R, Brenner R, Slayden O, Winkel C, Elger W. Role of nonhuman primate models in the discovery and clinical development of selective progesterone receptor modulators (SPRMs). Reprod Biol Endocrinol. 2006;4(Suppl 1):S8
  41. Oosterbaan H. An open-label study of the effects of a 24-day regimen of gestodene 60 microg/ethinylestradiol 15 microg on endometrial histological findings in healthy women. Eur J Contracept Reprod Health Care. 1999;4(Suppl 2):3–8
  42. Ludicke F, Johannisson E, Helmerhorst F, Campana A, Foidart J, Heithecker R. Effect of a combined oral contraceptive containing 3 mg of drospirenone and 30 microg of ethinyl estradiol on the human endometrium. Fertil Steril. 2001;76:102–107
  43. Rabe T, Johanisson E. The influence of ethinyl estradiol 0.03 mg and chlormadinone acetate 2 mg on the structure and histology of the endometrium. J Appl Ther. 2008;6:3–10
  44. Sullivan H, Furniss H, Spona J, Elstein M. Effect of 21-day and 24-day oral contraceptive regimens containing gestodene (60 microg) and ethinyl estradiol (15 microg) on ovarian activity. Fertil Steril. 1999;72:115–120
  45. Bitzer J. Belara—proven benefits in daily practice. Eur J Contracept Reprod Health Care. 2005;10(Supp 1):19–25
  46. Archer D, Maheux R, DelConte A, O'Brien F. A new low-dose monophasic combination oral contraceptive (Alesse) with levonorgestrel 100 micrograms and ethinyl estradiol 20 micrograms. North American Levonorgestrel Study Group (NALSG). Contraception. 1997;55:139–144
  47. Gallo M, Nanda K, Grimes D, Schulz K. 20 mcg versus >20 mcg estrogen combined oral contraceptives for contraception. Cochrane Database Syst Rev. 2005;CD003989
  48. Fotherby K. Twelve years of clinical experience with an oral contraceptive containing 30 micrograms ethinyloestradiol and 150 micrograms desogestrel. Contraception. 1995;51:3–12

PII: S0010-7824(10)00150-2

doi: 10.1016/j.contraception.2010.04.013

Contraception
Volume 82, Issue 4 , Pages 358-365 , October 2010

Article Tools

* Image Usage & Resolution